Medline Inc. Files 8-K: Material Agreements & Corporate Changes
Ticker: MDLN · Form: 8-K · Filed: Dec 22, 2025 · CIK: 2046386
Sentiment: neutral
Topics: material-agreement, corporate-governance, officer-changes, bylaws
TL;DR
Medline Inc. filed an 8-K on 12/16/25 detailing material agreements, officer changes, and bylaw amendments.
AI Summary
On December 16, 2025, Medline Inc. entered into a material definitive agreement. The company also reported on material modifications to the rights of security holders and changes related to directors and officers, including compensatory arrangements. Additionally, amendments to the company's articles of incorporation or bylaws and a change in fiscal year were noted.
Why It Matters
This filing indicates significant corporate actions and potential shifts in Medline Inc.'s structure or agreements, which could impact its operations and stakeholder rights.
Risk Assessment
Risk Level: medium — The filing covers multiple significant corporate events including material agreements, changes in officer/director roles, and amendments to governing documents, suggesting potential shifts in the company's structure or strategy.
Key Numbers
- 001-43022 — SEC File Number (Identifier for Medline Inc.'s filings)
- 33-1845288 — IRS Employer Identification No. (Tax identification for Medline Inc.)
Key Players & Entities
- Medline Inc. (company) — Registrant
- December 16, 2025 (date) — Earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 3 Lakes Drive, Northfield, IL (address) — Business and mailing address
FAQ
What is the nature of the material definitive agreement entered into by Medline Inc. on December 16, 2025?
The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the summary information.
What specific changes were made regarding directors or officers of Medline Inc.?
The filing notes the departure of directors or certain officers, the election of directors, and the appointment of certain officers, as well as compensatory arrangements for certain officers.
Were there any amendments to Medline Inc.'s articles of incorporation or bylaws?
Yes, the filing explicitly states 'Amendments to Articles of Incorporation or Bylaws' as an item of disclosure.
Did Medline Inc. change its fiscal year?
Yes, the filing lists 'Change in Fiscal Year' as one of the reported items.
What is the significance of the 'Material Modifications to Rights of Security Holders' mentioned in the filing?
This indicates that changes have been made that could affect the rights associated with Medline Inc.'s securities, the specifics of which would be detailed within the full filing.
Filing Stats: 1,940 words · 8 min read · ~6 pages · Grade level 10.4 · Accepted 2025-12-22 16:48:32
Key Financial Figures
- $0.0001 — stered Class A common stock, par value $0.0001 per share MDLN The Nasdaq Stock Mar
- $300,000 — ve Plan with a grant date fair value of $300,000. The RSUs will vest on March 30, 2027,
- $29.00 — ional shares) for cash consideration of $29.00 per share (net of underwriting discount
- $5,078 million — rom the issuance of 179,000,000 shares ($5,078 million) in the Offering to purchase an equival
- $731 million — which Medline Holdings has in turn used $731 million to repay in full all outstanding indebt
- $3,292 million — Company's New Euro Term Loan Facility, $3,292 million to repay a portion of the outstanding i
- $1,051 million — from the issuance of 37,034,482 shares ($1,051 million) and the issuance of 32,405,172 shares
- $919 million — and the issuance of 32,405,172 shares ($919 million) pursuant to the exercise in full by th
Filing Documents
- d933672d8k.htm (8-K) — 49KB
- d933672dex31.htm (EX-3.1) — 621KB
- d933672dex32.htm (EX-3.2) — 116KB
- d933672dex101.htm (EX-10.1) — 351KB
- d933672dex102.htm (EX-10.2) — 253KB
- d933672dex103.htm (EX-10.3) — 82KB
- d933672dex104.htm (EX-10.4) — 291KB
- d933672dex1051.htm (EX-10.5-1) — 129KB
- d933672dex1052.htm (EX-10.5-2) — 145KB
- d933672dex1053.htm (EX-10.5-3) — 132KB
- d933672dex1054.htm (EX-10.5-4) — 140KB
- d933672dex106.htm (EX-10.6) — 116KB
- 0001193125-25-328884.txt ( ) — 3065KB
- mdln-20251216.xsd (EX-101.SCH) — 2KB
- mdln-20251216_lab.xml (EX-101.LAB) — 18KB
- mdln-20251216_pre.xml (EX-101.PRE) — 11KB
- d933672d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 3.1 Amended and Restated Certificate of Incorporation of Medline Inc. 3.2 Amended and Restated Bylaws of Medline Inc. 10.1 Second Amended and Restated Limited Partnership Agreement of Medline Holdings, LP, dated as of December 16, 2025. 10.2 Tax Receivable Agreement, dated as of December 16, 2025, by and among Medline Inc. and each of the other persons from time to time party thereto. 10.3 Exchange Agreement, dated as of December 16, 2025, by and among Medline Inc., Medline Holdings, LP and holders of Common Units from time to time party thereto. 10.4 Registration Rights Agreement, dated as of December 16, 2025, by and among Medline Inc. and each of the other persons from time to time party thereto. 10.5.1 Director Nomination Agreement, dated as of December 16, 2025, between Medline Inc. and entities affiliated with Blackstone Inc. 10.5.2 Director Nomination Agreement, dated as of December 16, 2025, between Medline Inc. and entities affiliated with The Carlyle Group Inc. 10.5.3 Director Nomination Agreement, dated as of December 16, 2025, between Medline Inc. and entities affiliated with Hellman & Friedman LLC. 10.5.4 Family Director Nomination Agreement, dated as of December 16, 2025, between Medline Inc. and entities affiliated with the Mills Family. 10.6 Information and Access Agreement, dated as of December 16, 2025, between Medline Inc. and entities affiliated with Hux Investment Pte. Ltd. 10.7 Medline Inc. 2025 Omnibus Incentive Plan (incorporated by reference to Exhibit 4.3 filed with the Registrant's Registration Statement on Form S-8 filed with the Securities and Exchange Commission on December 16, 2025). 10.8 Medline Inc. 2025 Employee Stock Purchase Plan (incorporated by reference to Exhibit 4.4 filed with the Registrant's Registration Statement on Form S-8 filed with the Securities and Exchange Commission on December 16, 2025).
Signatures
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed by the undersigned hereunto duly authorized. Medline Inc. Date: December 22, 2025 By: /s/ Michael B. Drazin Name: Michael B. Drazin Title: Chief Financial Officer